Qui di seguito gli interventi e gli orari a cui per il nostro fuso orario dobbiamo aggiungere 5 ore.

Session I: Introduction, NIH Priorities, & Anti-sense Oligonucleotides
11:00 am, Matthew Gentry, PhD, U. of Kentucky College of Medicine: Opening comments
11:10 am, Miriam Leenders, PhD, NINDS/NICHD Program Officer
The NINDS commitment to basic research and rare diseases
11:30 am, Y. Paul Goldberg, MD/PhD, Ionis Pharmaceuticals, VP, Clinical Development
Progress to the Clinic: Antisense Oligonucleotide Suppression of Glycogen Synthase 1 to Treat Lafora Disease
12:00 pm, Berge A. Minassian, MD, UT-Southwestern, Pediatrics, Neurology, and Neuroscience
Silvie Nitschke, PhD, Minassian Group, UT-Southwestern
The winding pre-clinical road to an ASO therapy for Lafora disease

Session II: Clinical Insights, PME, Targeting Glycogen Synthesis
12:30 pm, Alison Dolce, MD, —Minassian Group, UT-Southwestern
Short talk: Lafora disease EEG in a pair of siblings, one effected, one yet not
12:45 pm, Subramaniam Ganesh, PhD, Indian Institute of Technology
PME genes, neuroinflammation, and epilepsy
1:15 pm, Olga Varea, PhD – Guinovart Group, IRB-Barcelona
Short talk: Suppression of glycogen synthesis as a treatment for LD
1:30 pm, Tom Hurley, PhD, Indiana University School of Medicine
Small molecule suppression of glycogen storage: structural and mechanistic studies

Session III: Repurposing, Novel Mechanisms, Novel Models, Clinical Insights
2:00 pm, Pascual Sanz, PhD, Institute of Biomedicine in Valencia-CSIC
Repurposing drugs: a disease-modifying strategy to ameliorate Lafora disease pathophysiology
2:30 pm, Joan Guinovart, PhD, IRB-Barcelona: Role of p62 in Lafora disease
3:00 pm, Jose M. Serratosa, MD/PhD, Fundación Jimenez Diaz Hospital
Generation and characterization of the first LD patient mutation mouse model
3:30 pm, Maria Machio, MD, – Fundación Jimenez Diaz Hospital, Short talk: Defining early stage LD EEG
3:45 pm, Antonio Delgado-Escueta, MD, UCLA Neurology: The five stages of Lafora disease
4:15 pm, Matthew S. Gentry, PhD, U. of Kentucky College of Medicine
Glycogenolysis defects in Lafora disease due to aberrant glucosamine metabolism